LataMed AI Corp. (OTC: LMED) provided an update on the implementation of its 5-for-1 forward stock split and mandatory share exchange process. As of July 7, 2026, the company has submitted all required documentation to FINRA, and management anticipates the corporate action will become effective within approximately one week, subject to FINRA's review. The forward stock split will be accompanied by a new CUSIP number (21116R404).
Shareholders holding shares through brokerage accounts are expected to have the exchange processed automatically through normal securities settlement. Registered book-entry shareholders will have their accounts updated by the transfer agent without needing to take action. Physical stock certificate holders are not required to surrender certificates immediately but must do so when they wish to transfer, sell, or exchange them; the transfer agent will then issue post-split shares under the new CUSIP. Detailed instructions will be provided by the transfer agent as the process progresses.
CEO Dr. Kevin Rodan Levy emphasized that the forward stock split and mandatory exchange are designed to support the company's capital structure and strategic initiatives. Management intends to focus on advancing the telemedicine platform and pursuing licensing opportunities for its CardioAI, PulmoAI, and NeuroAI platforms, aiming to build an integrated digital healthcare ecosystem in Latin America. The company encourages shareholders with questions to contact their brokerage or the transfer agent once detailed instructions are available. For more information, visit https://latamed.ai.
